Edition:
United Kingdom

GenMark Diagnostics Inc (GNMK.OQ)

GNMK.OQ on NASDAQ Stock Exchange Global Market

5.95USD
17 Jan 2019
Change (% chg)

$-0.04 (-0.67%)
Prev Close
$5.99
Open
$5.99
Day's High
$5.99
Day's Low
$5.87
Volume
51,877
Avg. Vol
111,051
52-wk High
$8.81
52-wk Low
$3.58

Latest Key Developments (Source: Significant Developments)

GenMark Diagnostics Sees FY 2018 Revenue About $70.8 Mln
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - GenMark Diagnostics Inc ::GENMARK DIAGNOSTICS PROVIDES PRELIMINARY OPERATIONAL AND FINANCIAL RESULTS FOR 2018.SEES Q4 2018 REVENUE ABOUT $19.4 MILLION.SEES FY 2018 REVENUE ABOUT $70.8 MILLION.SEES FY 2018 REVENUE UP 35 PERCENT.SEES Q4 2018 REVENUE UP 21 PERCENT.EPLEX REVENUE FOR Q4 OF 2018 EXPECTED TO BE APPROXIMATELY $12.1 MILLION, AN INCREASE OF APPROXIMATELY 110% VERSUS Q4 OF 2017.Q4 REVENUE VIEW $18.7 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $70.1 MILLION -- REFINITIV IBES DATA.  Full Article

Genmark Diagnostics Receives FDA 510(K) Market Clearance
Wednesday, 26 Dec 2018 

Dec 26 (Reuters) - GenMark Diagnostics Inc ::GENMARK DIAGNOSTICS RECEIVES FDA 510(K) MARKET CLEARANCE FOR ITS EPLEX BLOOD CULTURE IDENTIFICATION FUNGAL PATHOGEN PANEL.GENMARK DIAGNOSTICS INC - TWO OF THREE EPLEX BLOOD CULTURE IDENTIFICATION PANELS NOW CLEARED FOR MARKETING IN U.S..GENMARK DIAGNOSTICS INC - GENMARK'S BCID-GN PANEL WAS SUBMITTED TO FDA IN SEPTEMBER 2018 AND IS STILL CURRENTLY UNDER REVIEW..GENMARK DIAGNOSTICS INC - THIRD PANEL IS CURRENTLY UNDER REVIEW BY FDA AND CO CONTINUES TO EXPECT ITS CLEARANCE IN EARLY PART OF NEXT YEAR.  Full Article

Genmark Diagnostics Receives FDA 510(K) Market Clearance For Its Eplex Blood Culture Identification Gram-Positive Panel
Thursday, 20 Dec 2018 

GenMark Diagnostics Inc ::GENMARK DIAGNOSTICS RECEIVES FDA 510(K) MARKET CLEARANCE FOR ITS EPLEX BLOOD CULTURE IDENTIFICATION GRAM-POSITIVE PANEL.GENMARK DIAGNOSTICS - BCID-GN AND BCID-FP PANELS SUBMITTED TO FDA IN SEPTEMBER 2018 STILL CURRENTLY UNDER REVIEW.  Full Article

GenMark Diagnostics Files For Mixed Shelf Of Upto $150 Miln-SEC Filing
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - GenMark Diagnostics Inc ::GENMARK DIAGNOSTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

GenMark Diagnostics Q3 Loss Per Share $0.20
Monday, 29 Oct 2018 

Oct 29 (Reuters) - GenMark Diagnostics Inc ::GENMARK DIAGNOSTICS REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.20.Q3 REVENUE $15.8 MILLION VERSUS I/B/E/S VIEW $15.5 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.20 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $68 MILLION TO $72 MILLION.RECONFIRMING 2018 REVENUE GUIDANCE OF $68 TO $72 MILLION.GROSS MARGIN IS NOW EXPECTED TO BE IN 28-30% RANGE FOR 2018.RANGE OF EXPECTED EPLEX PLACEMENTS HAS BEEN NARROWED TO 150-160 NET NEW ANALYZERS FOR 2018.  Full Article

GenMark Diagnostics Says Co Entered Into Sixth Amendment To Loan And Security Agreement With Solar Senior Capital & Other Lenders
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - GenMark Diagnostics Inc ::GENMARK DIAGNOSTICS SAYS ON SEPT 28, CO ENTERED INTO SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT WITH SOLAR SENIOR CAPITAL & OTHER LENDERS.GENMARK DIAGNOSTICS -AMENDMENT EXTENDS INTEREST-ONLY PERIOD IN RESPECT OF AMOUNTS BORROWED UNDER AGREEMENT UNTIL JAN 1, 2020- SEC FILING.GENMARK DIAGNOSTICS - AGREEMENT ALSO EXTENDS FINAL MATURITY DATE ON WHICH ALL OF CO'S LIABILITIES UNDER AGREEMENT BECOME DUE UNTIL JAN 1, 2021.  Full Article

Genmark Diagnostics Announces FDA Submission Of Its ePlex Blood Culture Identification Gram Positive Panel
Thursday, 28 Jun 2018 

June 28 (Reuters) - GenMark Diagnostics Inc ::GENMARK DIAGNOSTICS ANNOUNCES FDA SUBMISSION OF ITS EPLEX BLOOD CULTURE IDENTIFICATION GRAM POSITIVE PANEL.GENMARK DIAGNOSTICS INC - ANTICIPATES FDA SUBMISSION OF GRAM NEGATIVE PANEL (BCID-GN) AND FUNGAL PATHOGEN PANEL (BCID-FP) IN Q3 AND Q4 THIS YEAR.  Full Article

GenMark Diagnostics Sees Q4 2017 Revenue About $16 Mln
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Genmark Diagnostics Inc ::GENMARK DIAGNOSTICS PROVIDES PRELIMINARY OPERATIONAL AND FINANCIAL RESULTS FOR 2017.SEES FY 2017 REVENUE ABOUT $52.5 MILLION.SEES Q4 2017 REVENUE ABOUT $16 MILLION.SEES FY 2017 REVENUE UP 7 PERCENT.SEES Q4 2017 REVENUE UP 8 PERCENT.Q4 REVENUE VIEW $15.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $51.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Genmark Diagnostics Entered Fifth Amendment To Loan And Security Agreement
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Genmark Diagnostics Inc ::GENMARK DIAGNOSTICS INC - ON DEC 13 CO ENTERED FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT WITH SOLAR SENIOR CAPITAL - SEC FILING.GENMARK DIAGNOSTICS INC - AS PER AMENDMENT, MATURITY DATE FOR LOAN AND SECURITY AGREEMENT EXTENDED TO MARCH 12, 2020.  Full Article

Genmark Diagnostics Q3 loss per share $0.28
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Genmark Diagnostics Inc :Genmark diagnostics reports third quarter 2017 results.Q3 loss per share $0.28.Q3 revenue rose 7.3 percent to $11.6 million.Q3 revenue view $14.6 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Sees fy 2017 revenue $51 million to $53 million.  Full Article